At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
botulinum toxin, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
In Brief
A Phase 2 clinical trial evaluating botulinum toxin, Type A and Vehicle for Lateral Canthal Lines, LCL and Crow's Feet. Completed, enrolled 38 participants across 3 sites.
Detailed Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, LCL, Crow's Feet
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedApr 2019
Primary CompletionMay 2019
Study CompletionOct 2019
TodayJul 2026
First PostedApr 11, 2019
Enrollment StartFeb 27, 2019
Primary CompletionMay 6, 2019
Study CompletionOct 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.2 years ago
Interventions
botulinum toxin, Type Abiological
topical liniment
Vehiclebiological
Vehicle Formulation